Alzheimer's disease (AD), a leading cause of dementia, increasingly challenges our healthcare systems and society. Traditional therapies aimed at single targets have fallen short owing to the complex, multifactorial nature of AD that necessitates simultaneous targeting of various disease mechanisms for clinical success. Therefore, targeting multiple pathologies at the same time could provide a synergistic therapeutic effect. The identification of new disease targets beyond the classical hallmarks of AD offers a fertile ground for the design of new multi-target drugs (MTDs), and building on existing compounds have the potential to yield in successful disease modifying therapies. This review discusses the evolving landscape of MTDs, focusing on their potential as AD therapeutics. Analysis of past and current trials of compounds with multi-target activity underscores the capacity of MTDs to offer synergistic therapeutic effects, and the flourishing genetic understanding of AD will inform and inspire the development of MTD-based AD therapies.

阿尔茨海默病 (AD) 是导致痴呆症的主要原因，它日益挑战着我们的医疗保健系统和社会。由于 AD 的复杂性、多因素性质，针对单一靶点的传统疗法已经不足，需要同时针对多种疾病机制才能获得临床成功。因此，同时针对多种病理可以提供协同治疗效果。超越AD经典标志的新疾病靶点的识别为新的多靶点药物（MTD）的设计提供了肥沃的土壤，并且在现有化合物的基础上构建有可能产生成功的疾病修饰疗法。这篇综述讨论了 MTD 的发展前景，重点关注其作为 AD 疗法的潜力。对具有多靶点活性的化合物的过去和当前试验的分析强调了 MTD 提供协同治疗作用的能力，并且对 AD 的丰富的遗传学理解将为基于 MTD 的 AD 疗法的开发提供信息和启发。